Literature DB >> 10537360

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

L Liu1, P Taverna, C M Whitacre, S Chatterjee, S L Gerson.   

Abstract

Previously we showed that a mismatch repair (MMR)-deficient cell line, HCT116 (hMLH1 mut), unlike a MMR wild-type cell line, SW480, was more resistant to the therapeutic methylating agent, temozolomide (TMZ), because the MMR complex fails to recognize TMZ-induced O6-methylguanine DNA adduct mispairings with thymine that arise after replication. TMZ also produces N7-methylguanine and N3-methyladenine adducts that are processed efficiently by the base excision repair (BER) system. After removal of the methylated base by methylpurine glycosylase, which creates the abasic or apurinic-apyrimidinic (AP) site, the phosphodiester bond is hydrolyzed immediately by AP endonuclease, initiating the repair of the AP site. Methoxyamine (MX) reacts with the abasic site and prevents AP endonuclease cleavage, disrupting DNA repair. MX potentiated the cytotoxic effect of TMZ with a dose modification factor (DMF) of 2.3+/-0.12 in SW480 and 3.1+/-0.16 in HCT116. When combined with O6-benzylguanine (BG), MX and TMZ dramatically increased TMZ cytotoxicity (65.8-fold) in SW480, whereas no additive effect was seen in HCT116. This suggests that N7-methylguanine and N3-methyladenine adducts are cytotoxic lesions in MMR-deficient and wild-type cells when BER is interrupted. Because poly(ADP-ribose) polymerase (PARP) aids in processing of DNA strand breaks induced during MMR and BER, we asked whether PARP inhibitors would also affect BER-mediated cell killing. We found that PARP inhibitors PD128763, 3-aminobenzimide, and 6-aminonicotinamide increased the sensitivity to TMZ in both HCT116 MMR-deficient cells and SW480 MMR wild-type cells. In HCT116 cells, PD128763 remarkably decreased resistance to TMZ, with a DMF of 4.7+/-0.2. However, the combination of PD128763, BG, and TMZ had no greater effect, indicating that persistent O6-methylguanine had no effect on cytotoxicity. In SW480, the DMF for TMZ cytotoxicity was 3.1+/-0.12 with addition of PD128763 and 36 with addition of PD128763 and BG. Synergy analysis by median effect plots indicated a high degree of synergy between TMZ and MX or PD128763. In contrast, 1,3-bis(2-chloroethyl)-1-nitrosourea combined with either MX or PD128763 showed little if any potentiation observed in the absence of BG in either cell line, suggesting that BER pathway has little impact on cytotoxic processing of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced adducts. These studies indicate that targeting BER with MX or PARP inhibitors enhances the cytotoxicity of methylating agents, even in MMR-deficient cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537360

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  51 in total

1.  A system for exposing molecules and cells to biologically relevant and accurately controlled steady-state concentrations of nitric oxide and oxygen.

Authors:  Vasileios Dendroulakis; Brandon S Russell; C Eric Elmquist; Laura J Trudel; Gerald N Wogan; William M Deen; Peter C Dedon
Journal:  Nitric Oxide       Date:  2012-06-21       Impact factor: 4.427

Review 2.  Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency.

Authors:  Julie K Horton; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2006-11-20

3.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Authors:  Daniel P Cahill; Kymberly K Levine; Rebecca A Betensky; Patrick J Codd; Candice A Romany; Linsey B Reavie; Tracy T Batchelor; P Andrew Futreal; Michael R Stratton; William T Curry; A John Iafrate; David N Louis
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

Review 4.  Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks.

Authors:  Michael D Wyatt; Douglas L Pittman
Journal:  Chem Res Toxicol       Date:  2006-12       Impact factor: 3.739

Review 5.  Chemosensitization of tumors by resveratrol.

Authors:  Subash C Gupta; Ramaswamy Kannappan; Simone Reuter; Ji Hye Kim; Bharat B Aggarwal
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

6.  Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.

Authors:  Nirmala Krishnamurthy; Lili Liu; Xiahui Xiong; Junran Zhang; Monica M Montano
Journal:  Cancer Biol Ther       Date:  2015-04-07       Impact factor: 4.742

Review 7.  Regulation of DNA Alkylation Damage Repair: Lessons and Therapeutic Opportunities.

Authors:  Jennifer M Soll; Robert W Sobol; Nima Mosammaparast
Journal:  Trends Biochem Sci       Date:  2016-11-02       Impact factor: 13.807

8.  The DNA repair enzyme MUTYH potentiates cytotoxicity of the alkylating agent MNNG by interacting with abasic sites.

Authors:  Alan G Raetz; Douglas M Banda; Xiaoyan Ma; Gege Xu; Anisha N Rajavel; Paige L McKibbin; Carlito B Lebrilla; Sheila S David
Journal:  J Biol Chem       Date:  2020-01-30       Impact factor: 5.157

9.  Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.

Authors:  Michelle J Clarke; Evan A Mulligan; Patrick T Grogan; Ann C Mladek; Brett L Carlson; Mark A Schroeder; Nicola J Curtin; Zhenkun Lou; Paul A Decker; Wenting Wu; E Ruth Plummer; Jann N Sarkaria
Journal:  Mol Cancer Ther       Date:  2009-01-27       Impact factor: 6.261

Review 10.  Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.

Authors:  Charles A Kunos; Evanthia Galanis; Jeffrey Buchsbaum; Qian Shi; Lewis C Strauss; C Norman Coleman; Mansoor M Ahmed
Journal:  J Neurooncol       Date:  2017-05-30       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.